Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435370 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
A Phase 3 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 179
- Enrollment target
NCT00435370 is a Phase 3 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 179 participants.
The verdict
NCT00435370, a Phase 3 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 179 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG Tropisetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435370
The ClinicalTrials.gov registry entry for NCT00435370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00435370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435370 about?
NCT00435370 is a clinical study titled "Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia". This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
What is the current status of trial NCT00435370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 179 participants. The study started on 2006-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00435370?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Tropisetron (DRUG).
Who is sponsoring clinical trial NCT00435370?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.